Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
Sign Up to like & getrecommendations! Published in 2020 at "Gastroenterology Report"
DOI: 10.1093/gastro/goaa049
Abstract: Abstract Background The epithelial-to-mesenchymal transition (EMT) status is associated with programmed death-1 ligand 1 (PD-L1) expression in various cancers. However, the role and molecular mechanism of PD-L1 in the EMT of sorafenib-resistant hepatocellular carcinoma (HCC)… read more here.
Keywords: hcc; sorafenib resistant; hepg2 huh7; huh7 cells ... See more keywords
HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Genomics"
DOI: 10.1155/2022/9451557
Abstract: Hepatocellular carcinoma (HCC) represents a common malignancy, and mechanisms of acquired sorafenib resistance during the treatment of HCC patients remain elusive. The present study performed integrated bioinformatics analysis and explored the potential action of heme… read more here.
Keywords: expression abc; hcc cells; hcc; sorafenib resistant ... See more keywords
Abstract 3146: Targeting ANXA3 in combination with sorafenib for the treatment of hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3146
Abstract: Sorafenib is the only FDA-approved tyrosine kinase inhibitor for targeted therapy in advanced HCC. Nevertheless, its efficacy is limited with only a modest improvement in patient outcome, likely due to acquired resistance. In-depth understanding of… read more here.
Keywords: sorafenib treatment; hcc; sorafenib resistant; treatment ... See more keywords
AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520622666220425124419
Abstract: Background This study is part of a larger research effort to explore the molecular mechanism of hepatocellular carcinoma, reduce drug resistance and seek new targets. Objective To investigate the effect and mechanism of fibroblast growth… read more here.
Keywords: hepatoma; receptor; cell; sorafenib resistant ... See more keywords
miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.3390/genes13081375
Abstract: Background: Hepatocellular carcinoma (HCC) is the second most common malignancy with increasing cancer deaths worldwide. HCC is mainly diagnosed at its advanced stage, and treatment with FDA-approved sorafenib, the multikinase inhibitor drug, is advised. Acquired… read more here.
Keywords: cell; autophagy glutamine; sorafenib resistant; sorafenib ... See more keywords
Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms231810378
Abstract: Thyroid carcinoma, a disease in which malignant cells form in the thyroid tissue, is the most common endocrine carcinoma, with papillary thyroid carcinoma (PTC) accounting for nearly 80% of total thyroid carcinoma cases. However, the… read more here.
Keywords: paclitaxel sorafenib; thyroid carcinoma; ptc; sorafenib resistant ... See more keywords
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24087069
Abstract: Thyroid cancer is generally curable and, in many cases, can be completely treated, although it can sometimes recur after cancer therapy. Papillary thyroid cancer (PTC) is known as one of the most general subtypes of… read more here.
Keywords: thyroid; anti cancer; sorafenib resistant; serca ... See more keywords